The Antiapoptotic Actions of Mood Stabilizers
Author:
- 1 August 2005
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1053 (1) , 195-204
Abstract
Abstract:Two primary drugs used to treat bipolar mood disorder are lithium and valproate. Emerging evidence supports the notion that both mood stabilizers have neuroprotective effects. In primary cultures of rat cerebellar granule cells and cortical neurons, lithium and valproate robustly and potently protect against glutamate‐induced,N‐methyl‐d‐aspartate (NMDA) receptor‐mediated excitotoxicity. The neuroprotective mechanisms involve inactivation of NMDA receptors through inhibition of NR2B tyrosine phosphorylation, activation of cell survival factors such as the PI 3‐kinase/Akt signaling pathway, and induction of neurotrophic/neuroprotective proteins, including brain‐derived neurotrophic factor, heat‐shock protein (HSP), and Bcl‐2. Both drugs are also effective against other forms of insults such as ER stress in neurally related cell types. The molecular targets likely involve glycogen synthase kinase‐3 (GSK‐3) and histone deacetylase (HDAC) for lithium and valproate, respectively. In a rat cerebral artery occlusion model of stroke, postinsult treatment with lithium or valproate reduces ischemia‐induced brain infarction, caspase‐3 activation, and neurological deficits, and these neuroprotective effects are associated with HSP70 upregulation and, in the case of valproate, HDAC inhibition. In a rat excitotoxic model of Huntington's disease in which an excitotoxin is infused into the striatum to activate NMDA receptors, short‐term lithium pretreatment is sufficient to protect against DNA damage, caspase activation, and apoptosis of striatal neurons, and this neuroprotection is concurrent with Bcl‐2 induction. Moreover, lithium treatment increases cell proliferation near the site of striatal injury, and some newborn cells have phenotypes of neurons and astroglia. Thus, lithium and valproate are potential drugs for treating some forms of neurodegenerative diseases.Keywords
This publication has 49 references indexed in Scilit:
- Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2The Pharmacogenomics Journal, 2005
- Lithium neuroprotection: molecular mechanisms and clinical implicationsExpert Reviews in Molecular Medicine, 2004
- Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neuronsThe Pharmacogenomics Journal, 2004
- Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein inductionJournal of Neurochemistry, 2004
- Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's diseaseMolecular Psychiatry, 2003
- Chronic Treatment With a Low Dose of Lithium Protects the Brain Against Ischemic Injury by Reducing Apoptotic DeathStroke, 2003
- Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical OpportunitiesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Loss of normal huntingtin function: new developments in Huntington's disease researchTrends in Neurosciences, 2001
- The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNSJournal of Neurochemistry, 1999
- Long-term biphasic effects of lithium treatment on phospholipase C-coupled m3-muscarinic acetylcholine receptors in cultured cerebellar granule cellsNeurochemistry International, 1993